 |
Medspeak by CMJAuthor: Chinese Medical Journal
The Chinese Medical Journal (CMJ) reports the latest advances in medical sciences and technology. Hear the researchers who have published with CMJ talk about their most recent breakthroughs, and catch up on the latest updates in the field of medicine on the Medspeak by CMJ podcast. Language: en-us Genres: Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Redefining Atopic Dermatitis Care: Monoclonal Antibody CM310 Offers Hope, with Dr. Jianzhong Zhang
Episode 4
Wednesday, 20 August, 2025
Will the humanized monoclonal antibody CM310 transform treatment outcomes for patients with atopic dermatitis? In this episode, we speak with Dr. Jianzhong Zhang, Professor at Peking University People’s Hospital, who introduces a breakthrough drug for atopic dermatitis called CM310 and discusses its potential to improve the quality of life for patients living with this chronic skin condition.In 2024, Dr. Zhang and his collaborators published the results of a pivotal clinical trial evaluating the efficacy and safety of CM310. The article is titled, “Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.” Guest: Dr. Jianzhong Zhang Host: John L Summary: We explore the potential of a monoclonal antibody drug—named CM310—for treating atopic dermatitis, focusing on the results of a clinical trial conducted in China and published in the Chinese Medical Journal.
